Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168034 | 0.89 | TSHR (0.54) | TDP1L3MBTL1LTA4HEPHX2TSHR | |
| SCHEMBL4069939 | 0.89 | TDP1 (0.64) | TDP1L3MBTL1LTA4HEPHX2TSHR | |
| SCHEMBL1839074 | 0.87 | TDP1 (0.59) | TDP1L3MBTL1LTA4HEPHX2TSHR | |
| SCHEMBL3438748 | 0.85 | TDP1 (0.60) | TDP1L3MBTL1TSHRHRH3HRH4 | |
| SCHEMBL4173446 | 0.83 | LTA4H (0.53) | TDP1L3MBTL1LTA4HEPHX2TSHR | |
| SCHEMBL4165517 | 0.83 | L3MBTL1 (0.55) | TDP1L3MBTL1LTA4HEPHX2TSHR | |
| SCHEMBL26086950 | 0.82 | TSHR (0.71) | LTA4HEPHX2TSHRIDO1LMNA | |
| SCHEMBL13825175 | 0.82 | KCNH2 (0.62) | TDP1L3MBTL1TSHRHRH3HRH4 | |
| SCHEMBL6510053 | 0.82 | KCNH2 (0.62) | TDP1L3MBTL1TSHRHRH3HRH4 | |
| SCHEMBL13570654 | 0.82 | L3MBTL1 (0.58) | TDP1L3MBTL1LTA4HEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| EP-2705012-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | Piramal Imaging SA (CH) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012150220-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | WO | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | SLC1A5, SLC6A19, BCAT2 | TDP1 3981/4885L3MBTL1 3249/4885LTA4H 2793/4885 |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | TDP1 3345/4885L3MBTL1 1880/4885LTA4H 3888/4885 |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | SLC5A2, SLC5A1, UGGT1 | TDP1 4296/4885L3MBTL1 2163/4885LTA4H 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.